Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06441630 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 4, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jan 31, 2025 to Sep 2025
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 17, 2024 to Jul 31, 2024
    v4
  2. Start date: Jun 17, 2024 to Sep 17, 2024v3
  3. Study description expanded, about 2 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Addpharma Inc.
28 trials monitored
See 1 trial at risk
Hypertension
1,925 trials monitored
See 99 trials at risk
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Trial Details
NCT Number NCT06441630
Lead Sponsor Addpharma Inc.
Conditions
(from sponsor)		 Essential Hypertension
Related terms Essential Hypertension
Enrollment 251 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov